With this new development, inhibition of BTK shifted patient options from broader treatments (chemotherapy or radiation) to a more targeted approach (kinase inhibitors), revolutionizing the treatment landscape of CLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.